

1 **Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During**
2 **Active Surveillance for Prostate Cancer**

3
4
5 Benjamin H. Press^a, Tashzna Jones^a, Olamide Olawoyin^a, Soum D. Lokeshwar^a, Syed N
6 Rahman^a, Ghazal Khajir^a, Daniel W. Lin^{b,c}, Matthew R. Cooperberg^{d,e}, Stacy Loeb^f, Burcu F.
7 Darst^g, Yingye Zheng^c, Ronald C. Chen^h, John S. Witteⁱ, Tyler M. Seibert^{j,k,l},
8 William J. Catalona^m, Michael S. Leapman^a, Preston C. Sprenkle^a
9

10
11 ^aDepartment of Urology, Yale School of Medicine, New Haven, Connecticut;

12 ^bDepartment of Urology, University of Washington, Seattle, Washington;

13 ^cFred Hutchinson Cancer Research Center, Cancer Prevention Program, Public Health Sciences,
14 Seattle, Washington;

15 ^dDepartment of Urology, University of California San Francisco, San Francisco, California;

16 ^eDepartment of Epidemiology and Biostatistics, University of California San Francisco, San
17 Francisco, California

18 ^fDepartments of Urology and Population Health, New York University Langone Health and
19 Manhattan Veterans Affairs Medical Center, New York, New York;

20 ^gUniversity of Southern California, Center for Genetic Epidemiology, Keck School of Medicine,
21 Los Angeles, California;

22 ^hDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas

23 ⁱDepartment of Epidemiology and Population Health, Stanford University, Palo Alto, California;

24 ^jDepartment of Radiation Medicine and Applied Sciences, University of California San Diego,
25 La Jolla, California;

26 ^kDepartment of Radiology, University of California San Diego, La Jolla, California;

27 ^lDepartment of Bioengineering, University of California San Diego, La Jolla, California;

28 ^mDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago,
29 Illinois
30

31 Corresponding Author:

32 Preston C. Sprenkle, MD

33 Associate Professor of Urology

34 Division Chief, Division of Urology at VA Connecticut Healthcare System

35 Director, Urology Research Fellowship

36 Director, Urologic Oncology Clinical Fellowship

37 Department of Urology

38 Yale School of Medicine

39 New Haven, Connecticut

40 Email: preston.sprenkle@yale.edu

41 Tel: 203.785.2815

42 Fax: 203.737.8035
43

44 **Keywords:**

45 **Word Count of abstract: 300**

46 **Word count of text: 2,461**

47 Abstract

48 **Background**

49 Although the Decipher genomic classifier has been validated as a prognostic tool for several
50 prostate cancer endpoints, little is known about its role in assessing risks of biopsy
51 reclassification among patients on active surveillance, a key event that often triggers treatment.

52 **Objective**

53 To evaluate the association between Decipher genomic classifier and biopsy Gleason upgrade
54 among patients on active surveillance.

55 **Design, Setting, and Participants**

56 Retrospective cohort study among patients with low- and favorable-intermediate-risk prostate
57 cancer on active surveillance who underwent biopsy-based Decipher testing as part of clinical
58 care.

59 **Outcomes measures and statistical analysis**

60 Any increase in biopsy Gleason grade group (GG). We evaluated the association between
61 Decipher score using univariable and multivariable logistic regression. We compared area under
62 the receiver operating characteristic curve (AUC) of models comprised of baseline clinical
63 variables with or without Decipher score.

64 **Results and limitations**

65 We identified 133 patients of median age 67.7 years and median PSA 5.6 ng/mL. At enrollment
66 75.9% were GG1 and 24.1 GG2. Forty-three patients experienced biopsy upgrade. On
67 multivariable logistic regression, Decipher score was significantly associated with biopsy
68 upgrade (OR 1.37 per 0.10 unit increase, 95% CI 1.05-1.79 p=0.02). Decipher score was
69 associated with upgrade among patients with biopsy Grade group 1, but not Grade Group 2

70 disease. The discriminative ability of a clinical model (AUC 0.63, 95% CI 0.51-0.74) was
71 improved with the integration of Decipher score (AUC 0.69, 95% CI 0.58-0.80).

72 **Conclusions**

73 The Decipher genomic classifier was associated with short-term biopsy Gleason upgrading
74 among patients on active surveillance.

75 **Patient summary**

76 The results from this study indicate that among patients with prostate cancer undergoing active
77 surveillance, those with higher Decipher scores were more likely to have higher-grade disease
78 found over time. These findings indicate that the Decipher test might be useful for guiding the
79 intensity of monitoring during active surveillance, such as more frequent biopsy for patients with
80 higher scores.

81

82 **Introduction**

83 Active surveillance is the recommended initial management strategy for most patients
84 with low-grade prostate cancer and an option for selected patients with favorable-intermediate
85 risk disease and is now adopted by the majority of eligible patients.¹ Evidence from randomized
86 trials and institutional cohort studies supports the long-term safety of active surveillance and its
87 effectiveness as a strategy to avoid or defer definitive treatment.^{2,3} Nonetheless, 20-60% of
88 patients who are initially enrolled in active surveillance ultimately experience reclassification of
89 their disease based on changes in biopsy Gleason grade, PSA levels, or cancer volume.^{4,5} As a
90 result, up to half of the patients undergo definitive treatment in the near term, most frequently
91 due to Gleason upgrading.⁶ A smaller number of patients with clinically low-risk features
92 ultimately experience clinically significant progression over time, underscoring the need for
93 close monitoring to detect early signs of reclassification.⁷ Estimating the risk of disease
94 reclassification during active surveillance based on standard clinical parameters is imperfect,
95 leading to patient anxiety, avoidable treatment, and imprecision in monitoring (e.g., over or
96 under-use of surveillance testing).⁸⁻¹⁰

97 Genomic classifiers measuring features associated with prostate cancer aggressiveness
98 developed largely in patients with high-risk disease provide robust predictions of disease
99 outcome, yet little is known about their role in estimating the trajectory of untreated favorable-
100 risk prostate cancer.¹¹ The Decipher classifier (GenomeDx Biosciences, Vancouver, BC,
101 Canada), is a tissue-based platform evaluating the expression of 22 genes selected from whole-
102 transcriptome analysis and reflect pathways involved in cellular proliferation, differentiation,
103 immune modulation, and androgen-receptor signaling. The test has been widely validated both as
104 a prognostic and predictive marker associated with several clinical outcomes, including adverse

105 pathology at prostatectomy, biochemical recurrence, metastasis, and prostate cancer mortality
106 after treatment.^{12,13} However, less information is available regarding their utility in predicting the
107 outcome of patients being managed with active surveillance. Such information would be useful
108 as a means to tailor the approaches to clinical management – potentially moderating surveillance
109 protocols for those at lowest-risk and intensifying or foregoing surveillance in patients most
110 likely to experience reclassification or disease progression.⁸

111 In this study, we aimed to evaluate the association between the Decipher genomic
112 classifier and biopsy outcomes among patients with favorable-risk prostate cancer.¹⁴ Analytic
113 and clinical validation of commercially available genomic tests were largely conducted using
114 archival tissue obtained in the era before widespread use of prostate magnetic resonance imaging
115 (MRI), an approach that significantly improves the accuracy of sampling and reduces the risk of
116 initial misclassification.^{5,15,16} Therefore, commensurate with current clinical practice, we further
117 sought to conduct our study among a contemporary cohort of patients managed with active
118 surveillance following an MRI-ultrasound fusion-guided prostate biopsy.

119

120 **Materials and Methods**

121 *Study Design and Patient Selection*

122 We performed a retrospective cohort study of patients enrolled on active surveillance for
123 prostate cancer who underwent Decipher testing. We identified subjects from a prospectively
124 maintained institutional repository of patients with known or suspected prostate cancer
125 undergoing prostate MRI and prostate biopsy at a single tertiary care center. The primary study
126 objective was to examine the association between a patient's baseline Decipher score (scale 0-1.0
127 units) and Gleason upgrading during active surveillance, defined as an increase in the Gleason

128 grade group on subsequent biopsy. The secondary objectives were to evaluate the performance of
129 clinical prediction models with or without the genomic classifier, and to identify a clinical
130 threshold for the Decipher score in predicting Gleason upgrading. In addition, we evaluated the
131 association between Gleason upgrade and the clinically reported Decipher risk groups: low
132 (<0.45), intermediate (0.45-0.60), and high (>0.60).

133 Of 1,432 patients undergoing prostate MRI-ultrasound fusion biopsy, we identified 133
134 who elected initial active surveillance with at least one additional biopsy and underwent
135 Decipher testing from July 2016 through November 2020. Patients with low-risk prostate cancer
136 (Gleason score \leq 3+3, clinical-stage T1 [cT1], PSA \leq 10 ng/mL) and select patients with
137 favorable intermediate-risk prostate cancer (Gleason score \leq 3+4 with \leq one core with Gleason
138 pattern 4, \leq cT2, PSA 10-20 ng/mL) detected on combined systematic and MRI-ultrasound-
139 fusion-targeted biopsy (MRF-TB) were enrolled into the active surveillance program and
140 included in an IRB-approved prospective data registry. The institutional surveillance protocol
141 consisted of semi-annual PSA testing, a confirmatory prostate biopsy within one year of
142 diagnosis, and subsequent prostate MRI and prostate biopsy on a yearly or biennial basis.
143 Protocols for MRI and MRF-TB were conducted in a manner previously described.¹⁷ Genomic
144 testing was routinely offered to patients considering active surveillance without restriction based
145 on disease characteristics. We compiled clinical, pathology, and sociodemographic information,
146 including prostate MRI findings and the Decipher score.

147 *Statistical Analysis*

148 We compiled clinicopathologic variables, Decipher scores, and biopsy upgrade status for
149 each patient. Categorical variables were reported as n (%); continuous variables were reported as
150 the median and interquartile range (IQR). We used McNemar's test for statistical analysis of

151 proportions, and the Kruskal–Wallis test was used for continuous variables. We constructed
152 multivariable logistic regression models to evaluate the association between baseline
153 characteristics, including the Decipher score and biopsy Gleason upgrading. Variables that were
154 significantly associated with upgrading on univariable analysis were included in the model, as
155 well as *a priori* variables shown to be associated with Gleason upgrading in prior studies (age,
156 PSA density, number of biopsy cores positive for cancer and prostate MRI findings). We
157 compared the performance of a baseline clinical model with the Decipher classifier alone, and a
158 combined model consisting of clinical parameters and Decipher score. We used Youden’s index
159 to identify a potential threshold of Decipher score that could be clinically used to identify
160 patients at greater risk for reclassification during active surveillance. All statistical analyses were
161 performed using SPSS version 27 IBM SPSS Statistics, Armonk, NY, USA).

162

163 **Results**

164 The study sample consisted of 133 patients initially managed with active surveillance
165 who received Decipher testing. The median age at enrollment was 67.7 years (IQR 62.4 – 71.4),
166 and the median PSA at diagnosis was 5.6 ng/mL (IQR 4.3 – 7.1), Table 1. In this cohort, 66
167 (49.6%) had Decipher testing performed on their initial diagnostic biopsy and 67 (50.4%) had
168 testing on a subsequent biopsy. The biopsy Gleason grade at enrollment was GG1 for 75.9% and
169 GG2 for 24.1%. The median interval between biopsies was 13.6 months (IQR 11.9-16.9), and the
170 median Decipher score was 0.39 (IQR 0.25-0.48). The distribution of reported Decipher risk
171 groupings was ‘low’ in 64.4%, ‘intermediate’ in 25.3%, and ‘high’ in 10.3% of patients. Changes
172 in prostate MRI PI-RADS scores occurred in 41 patients (30.7%).

173 In total, 43 patients (32.3%) experienced biopsy upgrading. The median Decipher score
174 among those who upgraded was 0.39 (IQR 0.25-0.46) as compared with 0.41 (IQR 0.32 – 0.54)
175 among patients who were not ($p=0.06$). The distribution of upgrading events did not differ
176 significantly by Decipher risk groups (28.6% [low risk], 34.3% [intermediate risk], 50.0% [high
177 risk], $p=0.27$). On univariable analysis, increasing Decipher score was associated with greater
178 odds of upgrading (OR 1.24 per 0.10 unit, 95% CI, $p=0.045$). When stratified by the diagnostic
179 Gleason grade group, the Decipher score was associated with upgrading among patients with
180 GG1, (OR 1.29 per 0.10 unit, $p=0.047$), but not among those with GG2 disease ($p=0.41$). On
181 multivariable logistic regression analysis, Decipher score remained significantly associated with
182 the odds of biopsy upgrading (OR 1.37 per 0.10 units, 95% CI $p=0.02$).

183 The baseline clinical model showed modest discrimination of biopsy upgrade (AUC 0.63,
184 95% CI 0.51-0.74). The AUC for Decipher alone was 0.60 (95% 0.49-0.70). A combined model
185 including Decipher score and clinical variables improved the AUC to 0.69 (95% CI 0.58-0.80).
186 Figure 1. A Decipher cutoff of 0.475 maximized sensitivity and specificity for the prediction of
187 biopsy upgrade while on AS. At a dichotomous threshold of 0.475, sensitivity and specificity for
188 biopsy upgrading were 41.9% and 78.9%, respectively, and showed modest discrimination of
189 biopsy upgrade (AUC = 0.60, 95%CI 0.52-0.69). Among patients with Decipher scores <0.475
190 versus ≥ 0.475 , the incidence of biopsy upgrading was 26.0% vs 48.6%, respectively, $p=0.02$).
191 On univariable analysis, Decipher scores greater than or equal to 0.475 were associated with
192 increased odds of biopsy upgrade (OR 2.69, $p = 0.01$, 95%CI 1.22-5.92). On multivariable
193 logistic regression analysis, Decipher scores above the cutoff of 0.475 were independently
194 associated with odds of biopsy upgrade (OR 3.71, 95% CI 1.45-9.50, $p=0.01$).

195

196 **Discussion**

197 In this study, we found that the Decipher genomic classifier was associated with
198 subsequent biopsy upgrading among patients enrolled on active surveillance for low-risk or
199 favorable-intermediate-risk prostate cancer. In this contemporary cohort of patients undergoing
200 prostate MRI-ultrasound fusion biopsy, the Decipher score stratified the risk of reclassification
201 independently of clinical features, including PSA density and MRI findings. Integration of the
202 Decipher score improved the discriminative performance of a model based on baseline clinical
203 parameters and prostate MRI, although overall performance remained modest. We further found
204 that, based on a lower distribution of Decipher scores in the active surveillance population,
205 reported risk groupings were not informative for estimating the probability of Gleason
206 upgrading. As a result, distinct cut points or regard for the classifier as a continuous measure of
207 risk may have the most utility in active surveillance. These data provide novel quantitative
208 information for possibly integrating this baseline genomic classifier information into clinical
209 counseling.

210 Among patients with GG1 but not GG2 prostate cancer electing active surveillance,
211 Decipher scores were independently associated with Gleason upgrading on a subsequent biopsy.
212 This additional predictive information may have greater utility in low-risk patients than low-
213 intermediate-risk patients that have a 2 to 4-fold increased risk of reclassification, based on
214 clinical and pathology parameters.^{18,19} Although a large body of evidence has accumulated
215 investigating the associations between the Decipher score and clinical and pathology outcomes,
216 there is little direct evidence concerning its short-term prognostic significance in active
217 surveillance patients. The findings from this study suggest that the Decipher classifier may be
218 useful in identifying patients whose initial biopsies may have been misclassified or will

219 experience progression of their disease in the short term. However, we did not identify a
220 significant association between Decipher score and biopsy upgrade among the subset of patients
221 with GG2 disease. This may reflect the smaller sample size relative to GG1 and lower power for
222 this comparison, the contributions of biopsy sampling leading by chance to the detection of a
223 higher proportion of Gleason pattern 4 disease, or the possibility that the Decipher score is
224 indeed not associated with further biopsy upgrade in this group.

225 The setting of this cohort within the contemporary era of MRI-ultrasound-fusion-guided
226 biopsy increases the generalizability of the results, as MRI imaging is increasingly used to
227 improve the initial assessment of cancer grade, but does not eliminate misclassification.⁵ Within
228 this context, we found that baseline clinical parameters—including PSA density, number of cores
229 positive for cancer, MRI findings and age—offered only marginal discriminative ability for the
230 prediction of biopsy upgrade but were improved by the addition of the Decipher classifier.
231 Therefore, further optimization of prediction tools for active surveillance outcomes remains an
232 important and still unfulfilled clinical need.^{20,21}

233 Our findings build upon prior studies of surrogate endpoints for active surveillance
234 candidacy. For example, Herlemann and colleagues evaluated 647 patients diagnosed with the
235 National Comprehensive Cancer Center Network (NCCN) with very-low, low-, and favorable-
236 intermediate-risk prostate cancer treated with initial prostatectomy. In this cohort, the Decipher
237 score was an independent predictor of adverse pathology, i.e., high-grade and/or high-stage at
238 prostatectomy, (OR 1.34 per 0.1 unit increase, 95% CI 1.11-1.63).¹² Similarly, Kim and
239 colleagues analyzed Decipher scores from the biopsies of 266 patients with NCCN very-low,
240 low-, and favorable-intermediate-risk prostate cancer and also reported that the Decipher score
241 was an independent predictor of adverse pathology on prostatectomy (odds ratio 1.29 per 10%

242 increase, 95% CI 1.03–1.61 per 0.1 unit increase).²² However, by directly evaluating outcomes
243 of patients actually on active surveillance, we identified a significant association of Decipher test
244 results and tumor upgrading. Furthermore, as reclassification events constitute the most
245 significant triggers for conversion to active treatment, our results may have implications for
246 questions of health-related quality of life and cost-effectiveness in future studies.

247 The reclassification events in our study were assessed over a relatively short interval after
248 enrollment in active surveillance. Nearly one-third of patients in this study experienced biopsy
249 Gleason upgrading – a larger proportion than reported from large, institutional cohorts such as
250 the multi-institutional Canary Prostate Active Surveillance Study in which 27% of patients
251 experienced Gleason reclassification at a median follow-up of 4.1 years.²³ This suggests that the
252 upgrading observed was largely due to initial biopsy sampling error rather than disease
253 progression.²⁴ On the other hand, serial molecular profiling of prostate biopsies using
254 immunohistochemistry and next-generation sequencing has also identified the potential
255 contributions of short-term clonal progression of low-grade disease.²⁵ Regardless of the cause of
256 upgrading, the potential role of a genomic classifier to enhance estimates of a patient’s trajectory
257 at the time of active surveillance addresses an important clinical need. The overall modest
258 performance of even a refined clinical model incorporating prostate MRI and genomic testing in
259 this study underscores the need to improve risk estimation for patients enrolled on active
260 surveillance.

261 We found that the distribution of Decipher scores among active surveillance patients is
262 narrower and, as would be expected, was clustered at the lower end of the risk distribution. As a
263 result, different groupings may be required for distinguishing risk among active surveillance
264 patients, as the existing reporting classifications may be better suited for the wider spectrum of

265 genomic risk. Although the Decipher score as a continuous variable (per 0.1 unit) was associated
266 with Gleason upgrading, significant differences could not be appreciated when using Decipher's
267 standard risk groups generated in clinical reporting (low, intermediate, and high) that are applied
268 in the setting of more advanced disease. Assessing a putative clinical cut point that would
269 maximize sensitivity and specificity in this select group of patients yielded a value of 0.475, a
270 binary classification in which values above this threshold were associated with a nearly four-fold
271 higher odds of biopsy upgrading. A theoretical clinical application of these findings would
272 include offering Decipher testing broadly to patients with Gleason 3+3 disease in whom
273 identifying disease reclassification would lead to actionable differences in management, such as
274 those with a stronger inclination for undergoing definitive treatment due to younger age, less
275 comorbidity, and preference. For those patients bearing the lowest risk of disease
276 reclassification, as assessed through clinical and genomic features such as a Decipher score
277 <0.475, reducing the intensity of surveillance by increasing intervals between biopsy, or
278 avoiding biopsy altogether, may be feasible. However, these findings require further study in
279 larger cohorts and over longer periods of surveillance, or explicit study in a randomized trial.

280 There are several limitations of this study. Selection of patients for Decipher testing may
281 not have occurred at random and could potentially favor use in patients at higher risk for disease
282 reclassification for whom testing was undertaken to confirm suitability for active surveillance.
283 However, Decipher testing was routinely offered without known systematic preference for those
284 at higher risk, and patient baseline disease characteristics are consistent with widely-accepted
285 criteria for adoption of active surveillance.⁶ A higher incidence of short-term reclassification also
286 was reported in prior studies of patients receiving genomic testing that may relate to the
287 preferential use of genomic testing in higher-risk populations.²⁶ In addition, we defined biopsy

288 upgrade as any increase in biopsy Gleason score, an approach used in prior studies, but this may
289 fail to account for more substantial changes of risk such as a simultaneous increase in tumor
290 volume.²⁷ Although all prostate MRI studies were reviewed by expert genitourinary radiologists
291 at our institution, a central re-review of studies was not conducted for this study to apply the
292 PRECISE criteria for MRI progression.²⁸ Lastly, there is an insufficient sample size and follow-
293 up to assess the meaningful distant longitudinal outcomes. Despite these limitations, strengths of
294 this study include novel data on Decipher testing with outcomes of patients enrolled in a
295 contemporary active surveillance program.

296

297 **Conclusion**

298 The Decipher genomic classifier score was associated with biopsy Gleason upgrading
299 among patients with low-risk prostate cancer enrolled in active surveillance who had undergone
300 MRI-enhanced biopsy procedures.

301

302

303 **Table 1.** Baseline characteristics of patients with favorable-risk prostate cancer undergoing active
304 surveillance and receiving Decipher genomic testing.
305

Variable	Value
Median age in years, (IQR)	67.7 (62.4 – 71.4)
BMI, median (IQR)	27.1 (25.0 – 30.5)
PSA (ng/mL), median (IQR)	5.6 (4.3 – 7.1)
Biopsy Gleason Grade Group 1, N(%)	101 (75.9)
Biopsy Gleason Grade Group 2, N(%)	32 (24.1)
Race/Ethnicity, N(%)	
White	120 (90.2)
Black/African-American	8 (6.0)
Latino	3 (2.3)
Other	2 (1.5)
Prostate Volume, median (IQR)	46.0 (32.6 – 59.0)
Decipher Score, median (IQR)	0.39 (0.39 – 0.48)
Decipher Risk Category	
Low (<0.45)	94 (64.4)
Intermediate (0.45-0.60)	37 (25.3)
High (>0.60)	15 (10.3)
<i>Abbreviations: IQR= interquartile range; BMI=body mass index; PSA=prostate specific antigen</i>	

306

307

308

309

310

311

312

313

314 **Table 2.** Comparison of characteristics among patients who did and did not experience biopsy Gleason
 315 upgrading during active surveillance.
 316

Variable	Did Not Experience Biopsy Gleason Upgrade (N = 90)	Biopsy Gleason Upgrade (N = 43)	P-value
Median Age (IQR)	68.0 (62.4 – 70.9)	66.3 (61.9 – 73.2)	0.93
Median PSA (ng/mL), (IQR)	5.6 (4.1 – 7.0)	5.6 (4.4 – 7.2)	0.97
Median BMI (IQR)	26.8 (24.7 – 30.4)	28.1 (25.3 – 30.9)	0.20
Median PSA Density (IQR)	0.12 (0.08 - .18)	0.12 (0.08 – 0.16)	0.69
Median Prostate Volume (IQR)	45.0 (33.5 – 57.1)	47.0 (31.0 – 60.0)	0.81
Decipher Risk Category, (%)			0.27
Low (<0.45)	60 (0.67)	24 (55.8)	
Intermediate (0.45-0.60)	23 (0.26)	12 (27.9)	
High (>0.60)	7 (0.08)	7 (16.3)	
Median Decipher (IQR)	0.39 (0.25 – 0.46)	0.41 (0.32 – 0.54)	0.06
Median Systematic Positive	2 (1 – 4)	3 (1 – 4)	0.53
Prostate MRI PI-RADS, N (%)			0.57
1-2	22 (25.0)	8 (18.6)	
3	7 (7.9)	5 (11.7)	
4	39 (44.4)	20 (46.5)	
5	20 (22.7)	10 (23.2)	
Increase in MRI PI-RADS Classification	22 (28.2)	10 (32.2)	0.68
Abbreviations: <i>IQR</i> = interquartile range; <i>BMI</i> =body mass index; <i>PSA</i> =prostate specific antigen			

317

318

319

320

321

322


323

324 **Table 3.** Multivariable logistic regression model examining factors associated with biopsy Gleason
325 upgrade during active surveillance.
326

Variable	Odds Ratio	95% Confidence Interval		p
		Lower	Upper	
Age	1.02	0.97	1.07	0.44
Baseline Prostate MRI PIRADS				0.77
1 and 2	Reference	-	-	
3	0.63	0.14	2.82	0.55
4-5	1.02	0.36	2.89	0.97
PSA Density (per 0.1 unit)	0.83	0.50	1.44	0.52
Decipher Score (per 0.1 unit)	1.37	1.05	1.79	0.02
≥3 Positive systematic biopsy cores	2.55	1.04	6.29	0.04
<i>Abbreviations: PI-RADS=Prostate Imaging Reporting and Data System</i>				

327
328
329
330
331
332
333
334
335
336
337
338

339 **Figure 1.** Discriminative performance of clinical models for the prediction of biopsy upgrade during
340 active surveillance with and without the integration of Decipher.
341



342

343

344

345

346

347

348

349

350

351

352

353

354

355 **References**

- 356
357 1. Chen RC, Rumble RB, Loblaw DA, et al. Active Surveillance for the Management of Localized
358 Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology
359 Clinical Practice Guideline Endorsement. *Journal of clinical oncology : official journal of the*
360 *American Society of Clinical Oncology*. 2016;34(18):2182-2190.
- 361 2. Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer,
362 1990-2013. *Jama*. 2015;314(1):80-82.
- 363 3. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC. Contemporary use of initial
364 active surveillance among men in Michigan with low-risk prostate cancer. *European urology*.
365 2015;67(1):44-50.
- 366 4. Timilshina N, Komisarenko M, Martin LJ, et al. Factors Associated with Discontinuation of
367 Active Surveillance among Men with Low-Risk Prostate Cancer: A Population-Based Study. *The*
368 *Journal of urology*. 2021;206(4):903-913.
- 369 5. Williams C, Khondakar NR, Daneshvar MA, et al. The Risk of Prostate Cancer Progression in
370 Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance
371 Imaging-Fusion and Systematic Biopsy. *The Journal of urology*. 2021;206(5):1157-1165.
- 372 6. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-
373 up of a large, active surveillance cohort with localized prostate cancer. *Journal of clinical*
374 *oncology : official journal of the American Society of Clinical Oncology*. 2010;28(1):126-131.
- 375 7. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year Outcomes after Monitoring, Surgery, or
376 Radiotherapy for Localized Prostate Cancer. *The New England journal of medicine*.
377 2016;375(15):1415-1424.
- 378 8. Cooperberg MR, Zheng Y, Faino AV, et al. Tailoring Intensity of Active Surveillance for Low-
379 Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. *JAMA oncology*.
380 2020;6(10):e203187.
- 381 9. Olsson H, Nordström T, Clements M, Grönberg H, Lantz AW, Eklund M. Intensity of Active
382 Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. *European*
383 *urology oncology*. 2020;3(5):640-647.
- 384 10. Rajwa P, Sprenkle PC, Leapman MS. When and How Should Active Surveillance for Prostate
385 Cancer be De-Escalated? *European urology focus*. 2021;7(2):297-300.
- 386 11. Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene
387 Expression Testing for Prostate Cancer. *JAMA oncology*. 2021;7(1):52-58.
- 388 12. Herlemann A, Huang HC, Alam R, et al. Decipher identifies men with otherwise clinically
389 favorable-intermediate risk disease who may not be good candidates for active surveillance.
390 *Prostate cancer and prostatic diseases*. 2020;23(1):136-143.
- 391 13. Jairath NK, Dal Pra A, Vince R, Jr., et al. A Systematic Review of the Evidence for the Decipher
392 Genomic Classifier in Prostate Cancer. *European urology*. 2021;79(3):374-383.
- 393 14. Washington SL, 3rd, Jeong CW, Lonergan PE, et al. Regional Variation in Active Surveillance
394 for Low-Risk Prostate Cancer in the US. *JAMA network open*. 2020;3(12):e2031349.
- 395 15. Bloom JB, Daneshvar MA, Lebastchi AH, et al. Risk of adverse pathology at prostatectomy in
396 the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate
397 cancer patients. *Urologic oncology*. 2021;39(10):729.e721-729.e726.
- 398 16. O'Connor LP, Wang AZ, Yerram NK, et al. Combined MRI-targeted Plus Systematic
399 Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance
400 for Prostate Cancer. *Urology*. 2020;144:164-170.
- 401 17. Hsiang W, Ghabili K, Syed JS, et al. Outcomes of Serial Multiparametric Magnetic Resonance
402 Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active
403 Surveillance. *European urology focus*. 2021;7(1):47-54.

- 404 18. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. Evaluating
405 the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial
406 Period of Surveillance. *The Journal of urology*. 2019;202(3):506-510.
- 407 19. Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J. Long-term Results of
408 Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening
409 Trial. *European urology*. 2016;70(5):760-766.
- 410 20. Chu CE, Loneragan PE, Washington SL, et al. Multiparametric Magnetic Resonance Imaging
411 Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
412 *European urology*. 2020;78(4):515-517.
- 413 21. Rajwa P, Pradere B, Quhal F, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to
414 Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-
415 analysis. *European urology*. 2021;80(5):549-563.
- 416 22. Kim HL, Li P, Huang HC, et al. Validation of the Decipher Test for predicting adverse pathology
417 in candidates for prostate cancer active surveillance. *Prostate cancer and prostatic diseases*.
418 2019;22(3):399-405.
- 419 23. Liss MA, Newcomb LF, Zheng Y, et al. Magnetic Resonance Imaging for the Detection of High
420 Grade Cancer in the Canary Prostate Active Surveillance Study. *The Journal of urology*.
421 2020;204(4):701-706.
- 422 24. Inoue LY, Trock BJ, Partin AW, Carter HB, Etzioni R. Modeling grade progression in an active
423 surveillance study. *Statistics in medicine*. 2014;33(6):930-939.
- 424 25. Salami SS, Tosoian JJ, Nallandhighal S, et al. Serial Molecular Profiling of Low-grade Prostate
425 Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. *European urology*.
426 2021;79(4):456-465.
- 427 26. Cedars BE, Washington SL, 3rd, Cowan JE, et al. Stability of a 17-Gene Genomic Prostate Score
428 in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. *The Journal of*
429 *urology*. 2019;202(4):696-701.
- 430 27. Leapman MS, Ameli N, Cooperberg MR, et al. Quantified Clinical Risk Change as an End Point
431 During Prostate Cancer Active Surveillance. *European urology*. 2017;72(3):329-332.
- 432 28. Moore CM, Giganti F, Albertsen P, et al. Reporting Magnetic Resonance Imaging in Men on
433 Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a
434 European School of Oncology Task Force. *European urology*. 2017;71(4):648-655.
- 435